“Old” Biotechnology to “New” Biotechnology: Continuum or Disjunction?

  • F. E. Young
  • H. I. Miller
Conference paper
Part of the NATO ASI Series book series (volume 18)

Abstract

Since the advent of recombinant DNA techniques and hybridoma technology gave rise more than a decade ago to “new” biotechnology, there has been much discussion of whether the products newly available should be regarded as refinements, or extensions, of previous ones, or as resulting from a technological disjunction. This conundrum is important because of its intimate connection to the question whether existing methods of risk analysis or risk assessment are applicable to or adequate for new processes and products. This is a pivotal issue, because the purpose of such risk assessment is to provide scientists, government regulators and others a measure of the safety attendant to the testing or use of a product, and to provide guidance as to the management of the risk that may be present.

Keywords

Risk Assessment Genetic Engineering Gypsy Moth Corn Plant Risk Assessment Method 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fiksel, J.R. and V.T. Covello, “An Overview and Evaluation of the Suitability and Applicability of Risk Assessment Methods for Environmental Applications of Biotechnology,” in, “The Suitability and Applicability of Risk Assessment Methods for Environmental Applications of Biotechnology,” V.T. Covello and J.R. Fiksel, eds., U.S. National Science Foundation, Washington, D.C., 1985.Google Scholar
  2. 2.
    The Suitability and Applicability of Risk Assessment Methods for Environmental Applications of Biotechnology, V.T. Covello and J.R. Fiksel, eds., U.S. National Science Foundation, Washington, D.C., 1985.Google Scholar
  3. 3.
    Federal Register 49, 50856 (1984).Google Scholar
  4. 4.
    Federal Register 51, 23302 (1986).Google Scholar
  5. 5.
    Miller, H.I., Pharmaceutical Engineering 6, 28 (1986).Google Scholar
  6. 6.
    Demain, A.L. and N.A. Solomon, Sci. Amer. 245, 66 (1981).CrossRefGoogle Scholar
  7. 7.
    Hardy, R.W.F. and D.J. Glass, Issues in Science and Technology 1, (1985).Google Scholar
  8. 8.
    Goodman, R.M., H. Hauptli, A. Crossway, and V.C. Knauf, Science 236, 48 (1987).CrossRefGoogle Scholar
  9. 9.
    McFadden, E.S., J. Am. Soc. Agron. 22, 1050 (1930).Google Scholar
  10. 10.
    Newell, C.A. and R. Hymowitz, Crop Sci. 22, 1062 (1982).CrossRefGoogle Scholar
  11. 11.
    Rick, C.M., J.W. DeVerna, R.T. Chetelat, M.A. Stevens, Proc. Nati. Acad. Sci. U.S.A. 83, 3580 (1986).CrossRefGoogle Scholar
  12. 12.
    Miller, H.I. and F.E. Young, JAMA 257, 2334 (1987).CrossRefGoogle Scholar
  13. 13.
    Health Impact of Biotechnology: Report of a WHO Working Group, Swiss Biotech. 2, 7 (1985).Google Scholar
  14. 14.
    Klingman, D.L. and J.R. Coulson, Plant Dis. 66, 1205 (1982).CrossRefGoogle Scholar
  15. 15.
    Betz, F., M. Levin, and M. Rogul, Recomb. DNA Tech. Bull. 6, 135 (1983).Google Scholar
  16. 16.
    Kilbourne, E.D., Epidemiology of Viruses Genetically Altered by Man — Predictive Principles, in Banbury Report 22, Genetically Altered Viruses and the Environment, Cold Spring Harbor Laboratory, 1985.Google Scholar
  17. 17.
    Sharpies, F.E., Science 235, 1329 (1987).Google Scholar
  18. 18.
    Davis, B.D., Science 193, 442 (1976).CrossRefGoogle Scholar
  19. 19.
    Kingsbury, D.T., Bio/Technology 4, 1071 (1986).Google Scholar
  20. 20.
    Kennedy, D., The Wall Street Journal, p. 11, October 29, 1987.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • F. E. Young
    • 1
  • H. I. Miller
    • 1
  1. 1.U.S.Food and Drug AdministrationRockvilleUSA

Personalised recommendations